Abstract

 
 
 
 Purpose: To investigate changes in neurological function and endothelin (ET) levels in cerebral infarction patients treated with combination of urinary kallidinogenase and edaravone.
 Methods: Two groups of acute cerebral infarction patients on admission in our hospital from May 2017 to July 2019 were enrolled in this study. The control group (44 patients) received edaravone, while the study group (44 patients) was given urinary kallidinogenase combined with edaravone. Hemorheological indices, NIHSS scores, cerebral edema area, and ET levels, as well as the clinical effects of the treatments were compared. Incidence of major cerebrovascular adverse events during the 26-month follow-up period after treatment was recorded.
 Results: Compared with the control group, the study group exhibited increase in shear whole blood viscosity, high shear whole blood viscosity and fibrinogen levels after the treatment (p < 0.05); however, lower NIHSS score, ET level and brain edema area were observed in the study group (p < 0.05). Total treatment effectiveness in the study and control groups was 95.45 and 79.55 %, respectively (p < 0.05). Fewer adverse cerebrovascular events were observed in patients in the study group (11.36 vs 29.55 %, p < 0.05). Kaplan-Meier survival curve analysis revealed a mean event-free period of 16.12 months for the study group and 12.41 months for the control group (χ2 = 14.868, p < 0.001).
 Conclusion: Urinary kallidinogenase combined with edaravone treatment yields a favorable effect in optimizing the hemorheological indices of cerebral infarction patients, reducing the degree of neurological deficits, and elevating ET levels.
 
 
 
Highlights
Cerebral infarction, known clinically as ischemic stroke, is a disorder in cerebral blood circulation
This study was carried out to investigate the effect of treatment using combination of urinary kallidinogenase and edaravone on changes in nerve function and endothelin levels in patients with acute cerebral infarction
After treatment, a decrease in low shear whole blood viscosity, high shear whole blood viscosity and fibrinogen levels in both groups was seen, in which the study group presented a greater degree of decline in comparison with the control group (p < 0.05)
Summary
Known clinically as ischemic stroke, is a disorder in cerebral blood circulation. The disease is common in the middle-aged and elderly populations, associated with low cure rate, high degree of morbidity, disability and mortality, At present, the clinical treatment for cerebral infarction involves prevention of infection, maintenance of anti-platelet aggregation, adequate brain nerve nutrition and blood lipid regulation. Edaravone is administrated along with other drugs in clinical use. A study has indicated that the use of urinary kallidinogenase along with edaravone substantially enhances cerebral microcirculation, diminishes damage to patients' nerve function and promotes endothelin levels, resulting in a higher degree of safety [5]. This study was carried out to investigate the effect of treatment using combination of urinary kallidinogenase and edaravone on changes in nerve function and endothelin levels in patients with acute cerebral infarction
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call